

Cardiovascular Disease, Lipoproteins, and Diabetes

Special Edition of The Review of Diabetic Studies, Summer-Fall 2013

Table of Contents

1. Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients by <i>Szu-chi Chen and Chin-Hsiao Tseng</i>	88
1. Introduction.....	88
2. Diabetes and dyslipidemia.....	90
3. Correlation between dyslipidemia and diabetic nephropathy.....	91
4. Correlation between renal disease and cardiovascular disease.....	93
5. Correlation between glucose control with lipid levels, diabetic nephropathy, and cardiovascular complications.....	94
6. Conclusions.....	95
2. The Role of Triglyceride in Cardiovascular Disease in Asian Patients with Type 2 Diabetes - A Systematic Review by <i>Ai-Hua Chen and Chin-Hsiao Tseng</i>	101
1. Introduction.....	101
2. Literature search.....	102
3. Findings.....	102
3.1 Triglyceride and coronary heart disease.....	103
3.2 Triglyceride and stroke.....	103
3.3 Triglyceride and peripheral arterial disease.....	103
3.4 Triglyceride and cardiovascular disease.....	103
4. Discussion.....	103
4.1 Triglyceride and cardiovascular disease in a non-diabetic population.....	103
4.2 Triglyceride and cardiovascular disease in diabetic patients.....	106
4.3 Pathophysiology of triglyceride in cardiovascular disease.....	106
4.4 Evidence of triglyceride control for preventing CVD in diabetes.....	107
5. Limitations.....	107
6. Conclusions.....	107
3. Dyslipoproteinemia and Impairment of Renal Function in Diabetic Kidney Disease: An Analysis of Animal Studies, Observational Studies, and Clinical Trials by <i>Chi-Chih Hung, Jer-Chia Tsai, Hung-Tien Kuo, Jer-Ming Chang, Shang-Jyh Hwang, and Hung-Chun Chen</i>	110
1. Introduction.....	110
2. Diabetic kidney disease versus diabetic nephropathy.....	110
3. Dyslipoproteinemia versus hyperlipidemia as a cause of diabetic kidney disease.....	111
4. Dyslipoproteinemia is prevalent in DKD and CKD.....	112
5. Lipid metabolism in diabetes and CKD.....	112
6. Glomerular atherosclerosis.....	112
7. Cell model of glomerular atherosclerosis: the role of mesangial cells and oxidized LDL.....	113
8. Animal and human models of dyslipoproteinemia-associated glomerulosclerosis.....	113
8.1 High-cholesterol diet rat model of hyperlipidemia with or without hemodynamic factors.....	113
8.2 Insulin-resistant rat model of hyperlipoproteinemia independent of hyperglycemia.....	113
8.3 Limitations of animal models.....	113
8.4 Abnormal lipoprotein structure and glomerulosclerosis.....	113
9. Dyslipoproteinemia and tubulointerstitial fibrosis.....	114
9.1 Dyslipoproteinemia-associated tubulointerstitial fibrosis.....	114
9.2 Dyslipoproteinemia superimposed on glomerular injury-associated tubulointerstitial fibrosis.....	114
10. Dyslipoproteinemia and renal function progression in observational studies.....	114
11. Statin treatment and renal outcomes in randomized controlled trials.....	115
12. Fibrate treatment and renal outcomes in randomized controlled trials.....	116
13. Summary of findings from studies on diabetic kidney disease.....	116
14. Conclusions.....	117

4. Dyslipidemia and Diabetic Retinopathy by <i>Yo-Chen Chang and Wen-Chuan Wu</i>	121
1. Introduction.....	121
2. Studies on traditional lipid abnormalities and diabetic retinopathy	122
2.1 The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) XIII.....	122
2.2 The Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.....	122
2.3 The United Kingdom Prospective Diabetes Study (UKPDS).....	122
2.4 The Atherosclerosis Risk in Communities Study (ARICS).....	122
2.5 The Cardiovascular Health Study (CHS).....	123
2.6 The Hoorn Study.....	124
2.7 A study from France.....	124
2.8 Results of the Diabetes Control and Complications Trial (DCCT).....	124
2.9 The Multi-Ethnic Study of Atherosclerosis (MESA).....	124
2.10 Results of the Chennai Urban Rural Epidemiology Study (CURES), Eye Study 2.....	124
2.11 A study from Turkey.....	124
2.12 A study from Macedonia.....	124
2.13 Results from the Singapore Malay Eye Study (SMES).....	124
2.14 A study from Romania.....	125
2.15 A study from North India.....	125
2.16 SN-DREAMS Report Number 13.....	125
2.17 A study from Australia.....	125
2.18 The Beijing Eye Study (BES).....	125
2.19 The ADVANCE Study.....	125
3. Possible mechanisms involving lipid and DR	126
4. Associations with nontraditional lipid markers.....	126
5. Lipid-lowering therapy and DR.....	128
5.1 Fibrates.....	128
5.2 Statins.....	128
6. Conclusions.....	129
5. Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment by <i>Sandra J. Hamilton and Gerald F. Watts</i>	133
1. Introduction.....	133
2. Endothelial function.....	133
2.1 Normal endothelial function.....	133
2.2 Measurement of endothelial function.....	134
3. Endothelial dysfunction.....	135
3.1 Pathogenesis of endothelial dysfunction.....	135
3.2 Predictive value of endothelial dysfunction.....	135
3.3 Endothelial dysfunction in type 2 diabetes.....	136
4. Therapeutic regulation of endothelial dysfunction in type 2 diabetes	138
4.1 Lifestyle interventions	138
4.2 Lipid-regulating therapy	141
- Hydroxymethylglutaryl (HMG)-CoA reductase inhibitors (statins).....	141
- Emerging LDL-cholesterol lowering therapies.....	142
- Fibric acid derivatives.....	142
- Nicotinic acid (niacin).....	143
- Omega-3 fatty acids.....	143
- Probucol.....	143
4.3 Antiglycemic agents and insulin sensitizers.....	143
4.4 Other emerging therapies for T2D.....	144
4.5 Combination therapies.....	145
- Statins and fibrates.....	145
- Statins and niacins.....	145
- Statins and antihypertensive agents.....	146
- Combination therapy with antioxidants.....	146
- Other combinations therapies.....	146
5. Conclusions.....	147

6. Reassessing the Benefits of Statins in the Prevention of Cardiovascular Disease in Diabetic Patients - A Systematic Review and Meta-Analysis by <i>Yu-Hung Chang, Ming-Chia Hsieh, Cheng-Yuan Wang, Kun-Cheng Lin, Yau-Jiunn Lee</i>	157
1. Introduction.....	157
2. Methods.....	158
2.1 Literature search.....	159
2.2 Study selection.....	159
2.3 Data synthesis and analysis.....	159
3. Results.....	162
3.1 Benefits of statin therapy in the protection of CVD.....	162
3.2 Effect of statin on the protection of CVD differentiated by diabetes status.....	163
3.3 Effect of statin on the primary and secondary prevention of CVD in diabetes.....	164
3.4 Effect of statin on CVD prevention in diabetic patients – trials in diabetes only.....	166
4. Discussion.....	166
7. Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia? by <i>Aris P. Agouridis, Christos V. Rizos, Moses S. Elisaf, Theodosios D. Filippatos</i>	171
1. Introduction.....	171
2. Methods.....	172
3. Effects of statins in patients with T2DM.....	172
4. Effects of fibrates in patients with T2DM.....	174
5. Effects of statin and fibrate combination on metabolic parameters in patients with mixed dyslipidemia and/or T2DM.....	174
5.1 Simvastatin plus fibrate combination treatment.....	176
5.2 Atorvastatin plus fibrate combination treatment.....	178
5.3 Rosuvastatin plus fibrate combination treatment.....	178
5.4 Pravastatin plus fibrate combination treatment.....	179
5.5 Fluvastatin plus fibrate combination treatment.....	180
5.6 Pitavastatin plus fibrate combination treatment.....	180
6. Effects of statin-fibrate combination on microvascular complications in patients with T2DM.....	180
7. Effects of statin-fibrate combination therapy on CVD risk in patients with T2DM.....	181
8. Safety.....	182
9. Conclusions.....	182
8. Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials by <i>Sandra J. Hamilton and Gerald F. Watts</i>	191
1. Introduction.....	191
2. Atherogenic dyslipidemia.....	191
3. Pathogenesis of atherogenic dyslipidemia in type 2 diabetes.....	192
3.1 Atherogenicity.....	193
3.2 Targeting atherogenic dyslipidemia.....	193
4. Guideline for the management of atherogenic dyslipidemia.....	193
5. Therapeutic regulation of atherogenic dyslipidemia in type 2 diabetes.....	194
5.1 Monotherapies.....	194
- Lifestyle interventions.....	194
- Lipid regulating therapy.....	194
5.2 Addressing residual cardiovascular risk with combination pharmacotherapy: recent clinical trials.....	196
- Statins and ezetimibe.....	196
- Statins and fibrates.....	196
- Statins and niacins.....	197
- Statins and n-3 fatty acids ethyl esters.....	198
6. Conclusions.....	198
9. New Frontiers in the Treatment of Diabetic Dyslipidemia by <i>Shu-Yi Wang, Ming-Chia Hsieh, Shih-Te Tu, Chieh-Sen Chuang</i>	204
1. Introduction.....	204
2. Current approaches to diabetic dyslipidemia.....	205
3. New lipid-lowering drugs based on old drug classes.....	205
3.1 Statins.....	205

3.2 Fibrates.....	206
3.3 Niacin/nicotinic acid.....	206
4. New classes of drugs: therapies for reducing LDL-cholesterol levels.....	207
4.1 Squalene synthase inhibitors.....	207
4.2 Microsomal transfer protein inhibitors.....	207
4.3 Thyroid hormone mimetics.....	208
4.4 Preprotein convertase subtilisin kexin-9 inhibitors (PCSK9).....	208
5. Therapies for raising HDL cholesterol.....	209
5.1 HDL-derived proteins and peptides.....	209
5.2 Combined peroxisomal proliferator activating receptor alpha-gamma agonists.....	209
5.3 Peroxisomal proliferator-activating receptor (PPAR) delta agonists.....	209
6. Conclusions.....	209
10. Paradoxical Negative HDL Cholesterol Response to Atorvastatin and Simvastatin Treatment in Chinese Type 2 Diabetic Patients by Yu-Hung Chang, Kun-Cheng Lin, Dao-Ming Chang, Chang-Hsun Hsieh, and Yau-Jiunn Lee	213
1. Introduction.....	213
2. Methods.....	214
2.1 Subjects.....	214
2.2 Statistical analysis.....	215
3. Results.....	215
4. Discussion.....	217